-
The U.S. Attorneys office in Western District of Washington state has announced that Richard W. Gibson, 42, of SeaTac, WA, pleaded guilty in federal court in Seattle to wrongful disclosure of individually identifiable health information for economic gain. The case is the first criminal conviction related to the health information privacy provisions of HIPAA that became effective in April 2003.
-
This case highlights the problems that can stem from traumatic lacerations, a common childhood injury.
-
Thomson American Health Consultants is offering an audio conference with the information necessary to help you recognize the ethical and regulatory issues related to working with children in clinical trials.
-
-
-
In an adjuvant breast cancer trial conducted more than 20 years ago, older patients were randomized to treatment with tamoxifen and prednisone or no adjuvant therapy. Now, at 21 years of follow-up, it is clear that disease-free and overall survival remain better for those who received treatment.
-
In this largest reported series of surgical Stage I UPSC patients, recurrence rates were lower than those published in previous studies, suggesting a potential benefit of comprehensive surgical staging in these patients. The risk of recurrence and the mean overall survival were similar between surgical Stage I UPSC patients who were managed conservatively and those treated with adjuvant radiation therapy.
-
-
Patients with elevated bilirubin treated with irinotecan have an increased risk of toxicity, and a dose reduction is recommended. Patients with elevated AST, creatinine or prior pelvic radiation do not appear to have increased sensitivity to irinotecan, but the data are not adequate to support a specific dosing recommendation.
-
Hepatocellular carcinoma is one of the most common malignancies worldwide, and, for those with advanced disease, treatment responses have been dismal. The current report of a trial of gemcitabine and oxaliplatin offers some hope. Using 2 different schedules of these agents, this study found an approximate 20% objective response rate with stable disease occurring in an additional 50%.
